HRP20190896T1 - Inhibitori sintaze aldosterona - Google Patents
Inhibitori sintaze aldosterona Download PDFInfo
- Publication number
- HRP20190896T1 HRP20190896T1 HRP20190896TT HRP20190896T HRP20190896T1 HR P20190896 T1 HRP20190896 T1 HR P20190896T1 HR P20190896T T HRP20190896T T HR P20190896TT HR P20190896 T HRP20190896 T HR P20190896T HR P20190896 T1 HRP20190896 T1 HR P20190896T1
- Authority
- HR
- Croatia
- Prior art keywords
- 3alkyl
- optionally substituted
- heterocyclyl
- compound according
- following
- Prior art date
Links
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 28
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 20
- 125000000623 heterocyclic group Chemical group 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 4
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- MESFXNGUDNODTJ-UHFFFAOYSA-N 2h-thiazine 1,1-dioxide Chemical compound O=S1(=O)NC=CC=C1 MESFXNGUDNODTJ-UHFFFAOYSA-N 0.000 claims 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 3
- 206010020571 Hyperaldosteronism Diseases 0.000 claims 3
- 229910006074 SO2NH2 Inorganic materials 0.000 claims 3
- 125000002393 azetidinyl group Chemical group 0.000 claims 3
- 208000033679 diabetic kidney disease Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 208000010496 Heart Arrest Diseases 0.000 claims 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 2
- 206010021263 IgA nephropathy Diseases 0.000 claims 2
- 206010065673 Nephritic syndrome Diseases 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 206010061989 glomerulosclerosis Diseases 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims 1
- 208000016998 Conn syndrome Diseases 0.000 claims 1
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 claims 1
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000003205 diastolic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000013846 primary aldosteronism Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (21)
1. Spoj, naznačen time, da je predstavljen formulom I:
u kojoj:
R1 je odabran od –C(O)NH2, -C(O)NH(CH3) i –CN;
R2 je –(X)-R4, gdje
-(X)- je veza, -CH2-, ili –O-; i
R4 je odabran od sljedećih:
-H;
C1-3alkil, opcionalno supstituiran s jednom do četiri skupine odabrane od –F, –OH, i
–SO2C1-3alkil;
halogen;
-CN;
-SO2C1-3alkil;
-C(O)N(C1-3alkil)2, uz uvjet da –(X)- nije –O-;
-NHC(O)R5 ili –N(CH3)C(O)R5, uz uvjet da –(X)- je –CH2- i pri čemu je R5 odabran od
C3-6cikloalkila i C1-3alkila opcionalno supstituiranog s jednom do tri –F skupine;
-NHSO2C1-3alkil;
-CH(ciklopropil)NHSO2C1-3alkil;
-OCH2C(O)N(C1-3alkil)2, uz uvjet da –(X)- je –CH2-;
-S(=O)(=NH)CH3, uz uvjet da –(X)- je –CH2-;
heterociklil odabran od sljedećih: tetrahidropiranil, tetrahidrofuranil, pirolidinil,
1,1-diokso[1,2]-tiazin, morfolinil, oksazolidinil, piperidinil, azetidinil, pri čemu je navedeni heterociklil opcionalno supstituiran s jednom do tri skupine odabrane od sljedećih: –C(O)C1-3alkil, halogen, -OH, okso i C1-3alkil;
-C(O)-heterociklil, uz uvjet da –(X)- je –CH2, gdje je navedeni heterociklil odabran od
sljedećih: morfolin-4-il, pirolidin-1-il i piperidin-1-il, opcionalno supstituiranih s jednom ili dvije skupine odabrane od –F i -OH;
C3-6cikloalkil opcionalno supstituiran s –CN ili –OH; i
fenil, opcionalno supstituiran s –SO2NH2; i
R3 je H, ili C1-3alkil opcionalno supstituiran s -OH; ili
R2 i R3 zajedno tvore anelirani peteročlani cikloalkil-prsten opcionalno supstituiran s
–OH;
ili njegova sol ili njegov stereoizomer.
2. Spoj prema zahtjevu 1, naznačen time, da:
R1 je –C(O)NH2 ili –CN;
R2 je –(X)-R4, gdje
-(X)- je veza, i
R4 je odabran od sljedećih:
-CH3;
-CF3;
-CHF2;
-CH2OH;
-CH(OH)CH3;
-CH(OH)CF3;
-F;
-CN;
heterociklil odabran od tetrahidropiranila i pirolidinila, gdje je navedeni heterociklil opcionalno supstituiran s jednom do tri skupine odabrane od sljedećih: C1-3alkil, halogen, -OH i okso;
C3-6cikloalkil opcionalno supstituiran s –CN ili –OH; i
fenil, opcionalno supstituiran s –SO2NH2; ili
-(X)- je O, i
R4 je odabran od sljedećih:
C1-3alkil;
-CH2SO2C1-3alkil ; i
heterociklil odabran od tetrahidropiranila, tetrahidrofuranila, pirolidinila, piperidinila, i azetidinila, gdje je navedeni heterociklil opcionalno supstituiran s jednom do tri skupine odabrane od sljedećih: –C(O)C1-3alkil, halogen, -OH, okso i C1-3alkil; ili
X je (–CH2-), i
R4 je odabran od sljedećih:
-SO2C1-3alkil ;
-C(O)N(C1-3alkil)2;
-NHC(O)R5 ili –N(CH3)C(O)R5, gdje R5 je odabran od ciklopropila i C1-3alkila opcionalno supstituiranog s jednom do tri –F skupine;
-OCH2C(O)N(C1-3alkil)2;
-NHSO2C1-3alkil;
-S(=O)(=NH)CH3;
heterociklil odabran od pirolidinila, 1,1-diokso[1,2]-tiazina, morfolinila i oksazolidinila, gdje je navedeni heterociklil opcionalno supstituiran s jednom do tri skupine odabrane od
sljedećih: –C(O)C1-3alkil, halogen, -OH, okso i C1-3alkil; i
-C(O)-heterociklil, gdje je heterociklil odabran od morfolin-4-ila, pirolidin-1-ila i piperidin-1-ila, opcionalno supstituiranih s jednom ili dvije skupine odabrane od –F i
–OH; i
R3 je H ili C1-3alkil opcionalno supstituiran s -OH;
ili njegova sol ili njegov stereoizomer.
3. Spoj prema zahtjevu 1 ili 2, naznačen time, da:
R2 je –(X)-R4, gdje
-(X)- je veza, i
R4 je odabran od sljedećih:
-CF3;
-CHF2;
-CH2OH;
-CH(OH)CH3;
-CH(OH)CF3;
-F;
-CN;
heterociklil odabran od tetrahidropiranila i pirolidinila, gdje je navedeni heterociklil supstituiran s jednom do tri skupine odabrane od C1-3alkila, -F, -OH i okso;
C3-6cikloalkil, supstituiran s –CN ili –OH; i
fenil, opcionalno supstituiran s –SO2NH2; i
R3 je H, ili C1-3alkil opcionalno supstituiran s -OH;
ili njegova sol ili njegov stereoizomer.
4. Spoj prema bilo kojem od zahtjeva 1, 2 ili 3, naznačen time, da:
R2 je –(X)-R4, gdje
-(X)- je O, i
R4 je odabran od sljedećih:
C1-3alkil;
-CH2SO2C1-3alkil ; i
heterociklil odabran od tetrahidropiranila, tetrahidrofuranila, pirolidinila, piperidinila, i azetidinila, gdje je navedeni heterociklil opcionalno supstituiran s –C(O)C1-3alkilom; i
R3 je H, ili C1-3alkil opcionalno supstituiran s -OH;
ili njegova sol ili njegov stereoizomer.
5. Spoj prema bilo kojem od zahtjeva 1 do 4, naznačen time, da:
R2 je –(X)-R4, gdje
X je (–CH2-), i
R4 je odabran od sljedećih:
-SO2C1-3alkil ;
-C(O)N(C1-3alkil)2;
-NHC(O)R5 ili –N(CH3)C(O)R5, gdje R5 je odabran od ciklopropila i C1-3alkila opcionalno supstituiranog s jednom do tri –F skupine ;
-OCH2C(O)N(C1-3alkil)2;
-NHSO2C1-3alkil;
-S(=O)(=NH)CH3;
heterociklil odabran od pirolidinila, 1,1-diokso[1,2]-tiazina, morfolinila i oksazolidinila, gdje je navedeni heterociklil opcionalno supstituiran s jednom do dvije skupine odabrane od okso i C1-3alkila; i
-C(O)-heterociklil, gdje je heterociklil odabran od morfolin-4-ila, pirolidin-1-ila i piperidin-1-ila, opcionalno supstituiranih s jednom ili dvije skupine odabrane od –F i
–OH; i
R3 je H, ili C1-3alkil opcionalno supstituiran s -OH;
ili njegova sol ili njegov stereoizomer.
6. Spoj prema bilo kojem od zahtjeva 1 do 5, naznačen time, da:
R1 je –C(O)NH2;
ili njegova sol ili njegov stereoizomer.
7. Spoj prema bilo kojem od zahtjeva 1 do 5, naznačen time, da:
R1 je –CN;
ili njegova sol ili njegov stereoizomer.
8. Spoj prema zahtjevu 1, naznačen time, da je odabran iz skupine koju sačinjavaju:
ili njihova farmaceutski prihvatljiva sol ili njihov stereoizomer.
9. Spoj prema zahtjevu 8, naznačen time, da je odabran iz skupine koju sačinjavaju spojevi pod brojevima 1, 5 ,12, 29, 37, 43, 56, 61 i 62 ili njihova farmaceutski prihvatljiva sol ili njihov stereoizomer.
10. Spoj prema zahtjevu 1, naznačen time, da spoj je
.
11. Spoj prema zahtjevu 1, naznačen time, da spoj je
.
12. Spoj prema zahtjevu 1, naznačen time, da spoj je
.
13. Spoj prema zahtjevu 1, naznačen time, da spoj je
.
14. Spoj prema zahtjevu 1, naznačen time, da spoj je
.
15. Spoj prema zahtjevu 1, naznačen time, da spoj je
.
16. Farmaceutski prihvatljiva sol, naznačena time, da je ona od spoja u skladu s bilo kojim od zahtjeva 1 do 15.
17. Farmaceutski sastav, naznačen time, da obuhvaća spoj u skladu s bilo kojim od zahtjeva 1 do 15 i farmaceutski prihvatljiv ekscipijent ili nosač.
18. Spoj prema bilo kojem od zahtjeva 1 do 15, naznačen time, da se upotrebljava kao lijek.
19. Spoj prema bilo kojem od zahtjeva 1 do 15, naznačen time, da se upotrebljava u postupku liječenja bolesti ili poremećaja koja/koji se može ublažiti putem inhibicije sintaze aldosterona, te koja/koji je odabran/a od sljedećih: dijabetička nefropatija, glomeruloskleroza, glomerulonefritis, IGA-nefropatija, nefritički sindrom, fokalna segmentalna glomeruloskleroza (FSGS), hipertenzija, pulmonarna arterijska hipertenzija, Connov sindrom, sistolički zastoj srca, dijastolički zastoj srca, lijeva ventrikularna disfunkcija, lijeva ventrikularna ukočenost i fibroza, lijeve ventrikularne abnormalnosti kod punjenja, arterijska ukočenost, ateroskleroza i kardiovaskularni morbiditet povezan s primarnim ili sekundarnim hiperaldosteronizmom, adrenalna hiperplazija te primarni i sekundarni hiperaldosteronizam.
20. Spoj za uporabu prema zahtjevu 19, naznačen time, da je bolest ili poremećaj odabran/a od sljedećih: dijabetička nefropatija, glomeruloskleroza, glomerulonefritis, IGA-nefropatija, nefritički sindrom, fokalna segmentalna glomeruloskleroza (FSGS).
21. Spoj za uporabu prema zahtjevu 19, naznačen time, da bolest je dijabetička nefropatija.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462064234P | 2014-10-15 | 2014-10-15 | |
| EP15785014.0A EP3207039B1 (en) | 2014-10-15 | 2015-10-14 | Aldosterone synthase inhibitors |
| PCT/US2015/055421 WO2016061161A1 (en) | 2014-10-15 | 2015-10-14 | Aldosterone synthase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190896T1 true HRP20190896T1 (hr) | 2019-07-12 |
Family
ID=54352516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190896TT HRP20190896T1 (hr) | 2014-10-15 | 2019-05-14 | Inhibitori sintaze aldosterona |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9745289B2 (hr) |
| EP (1) | EP3207039B1 (hr) |
| JP (1) | JP6279812B2 (hr) |
| KR (1) | KR102441634B1 (hr) |
| CN (1) | CN107108587B (hr) |
| AP (1) | AP2017009829A0 (hr) |
| AR (1) | AR102266A1 (hr) |
| AU (1) | AU2015333611B2 (hr) |
| CA (1) | CA2964754C (hr) |
| CL (1) | CL2017000827A1 (hr) |
| CO (1) | CO2017003305A2 (hr) |
| CY (1) | CY1121650T1 (hr) |
| DK (1) | DK3207039T3 (hr) |
| EA (1) | EA031766B1 (hr) |
| ES (1) | ES2724555T3 (hr) |
| HR (1) | HRP20190896T1 (hr) |
| HU (1) | HUE043783T2 (hr) |
| IL (1) | IL251200B (hr) |
| LT (1) | LT3207039T (hr) |
| ME (1) | ME03381B (hr) |
| MX (1) | MX369025B (hr) |
| NZ (1) | NZ729688A (hr) |
| PE (1) | PE20170696A1 (hr) |
| PH (1) | PH12017500595A1 (hr) |
| PL (1) | PL3207039T3 (hr) |
| PT (1) | PT3207039T (hr) |
| RS (1) | RS58651B1 (hr) |
| SG (1) | SG11201701850UA (hr) |
| SI (1) | SI3207039T1 (hr) |
| TR (1) | TR201907755T4 (hr) |
| TW (1) | TWI731842B (hr) |
| UA (1) | UA118717C2 (hr) |
| WO (1) | WO2016061161A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6707084B2 (ja) * | 2014-12-02 | 2020-06-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルドステロンシンターゼ阻害薬 |
| CN113767095A (zh) | 2019-05-01 | 2021-12-07 | 勃林格殷格翰国际有限公司 | (r)-4-溴苯磺酸(2-甲基环氧乙烷-2-基)甲酯 |
| CN116438200A (zh) | 2020-09-10 | 2023-07-14 | 普雷西里克斯公司 | 针对fap的抗体片段 |
| AU2022415313A1 (en) | 2021-12-14 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors for treating chronic kidney disease |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR073629A1 (es) * | 2008-10-07 | 2010-11-17 | Schering Corp | Analogos de benzodioxano moduladores de receptores adrenergicos alfa 2c, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades respiratorias, alergicas, cardiacas, parkinson y/o alzheimer, entre otras |
| SG175925A1 (en) * | 2009-05-15 | 2011-12-29 | Novartis Ag | Aryl pyridine as aldosterone synthase inhibitors |
| BR112014013136B1 (pt) * | 2011-11-30 | 2020-05-26 | F. Hoffmann-La Roche Ag | Novos derivados de dihidroisoquinolina-1-ona biciclicos |
| US9550750B2 (en) | 2012-10-05 | 2017-01-24 | Merck Sharp & Dohme Corp. | Indoline compounds as aldosterone synthase inhibitors |
| AU2014219020A1 (en) | 2013-02-22 | 2015-07-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US9181272B2 (en) * | 2013-04-30 | 2015-11-10 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
| ES2684050T3 (es) * | 2014-07-24 | 2018-10-01 | Boehringer Ingelheim International Gmbh | Inhibidores de aldosterona sintasa |
-
2015
- 2015-10-14 KR KR1020177012975A patent/KR102441634B1/ko active IP Right Grant
- 2015-10-14 HU HUE15785014A patent/HUE043783T2/hu unknown
- 2015-10-14 TR TR2019/07755T patent/TR201907755T4/tr unknown
- 2015-10-14 LT LTEP15785014.0T patent/LT3207039T/lt unknown
- 2015-10-14 UA UAA201704599A patent/UA118717C2/uk unknown
- 2015-10-14 WO PCT/US2015/055421 patent/WO2016061161A1/en active Application Filing
- 2015-10-14 EA EA201790830A patent/EA031766B1/ru not_active IP Right Cessation
- 2015-10-14 SI SI201530696T patent/SI3207039T1/sl unknown
- 2015-10-14 NZ NZ729688A patent/NZ729688A/en unknown
- 2015-10-14 PL PL15785014T patent/PL3207039T3/pl unknown
- 2015-10-14 CA CA2964754A patent/CA2964754C/en active Active
- 2015-10-14 JP JP2017520427A patent/JP6279812B2/ja active Active
- 2015-10-14 PT PT15785014T patent/PT3207039T/pt unknown
- 2015-10-14 AP AP2017009829A patent/AP2017009829A0/en unknown
- 2015-10-14 US US14/882,486 patent/US9745289B2/en active Active
- 2015-10-14 ME MEP-2019-121A patent/ME03381B/me unknown
- 2015-10-14 ES ES15785014T patent/ES2724555T3/es active Active
- 2015-10-14 MX MX2017004852A patent/MX369025B/es active IP Right Grant
- 2015-10-14 CN CN201580053796.XA patent/CN107108587B/zh active Active
- 2015-10-14 SG SG11201701850UA patent/SG11201701850UA/en unknown
- 2015-10-14 DK DK15785014.0T patent/DK3207039T3/en active
- 2015-10-14 TW TW104133758A patent/TWI731842B/zh active
- 2015-10-14 RS RS20190501A patent/RS58651B1/sr unknown
- 2015-10-14 EP EP15785014.0A patent/EP3207039B1/en active Active
- 2015-10-14 AU AU2015333611A patent/AU2015333611B2/en active Active
- 2015-10-14 AR ARP150103319A patent/AR102266A1/es unknown
- 2015-10-14 PE PE2017000710A patent/PE20170696A1/es unknown
-
2017
- 2017-03-15 IL IL251200A patent/IL251200B/en active IP Right Grant
- 2017-03-31 PH PH12017500595A patent/PH12017500595A1/en unknown
- 2017-04-05 CL CL2017000827A patent/CL2017000827A1/es unknown
- 2017-04-05 CO CONC2017/0003305A patent/CO2017003305A2/es unknown
-
2019
- 2019-05-14 HR HRP20190896TT patent/HRP20190896T1/hr unknown
- 2019-05-24 CY CY20191100554T patent/CY1121650T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190896T1 (hr) | Inhibitori sintaze aldosterona | |
| HRP20191579T1 (hr) | Spojevi kao modulatori za ror gama | |
| PE20220143A1 (es) | Agonistas de glp-1r y usos de los mismos | |
| CO2017011093A2 (es) | Derivados de 6,7-dihidropirido [2,1-a]isoquinolin-2-ona como antagonistas del receptor gpr84, y composiciones que los contienen | |
| AR109348A1 (es) | Sulfonilureas y compuestos relacionados y sus usos | |
| UY38297A (es) | Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos | |
| HRP20170403T1 (hr) | SUPSTITUIRANI BENZOAZEPINI KAO MODULATORI TOLL-u SLIČNIH RECEPTORA | |
| PE20210414A1 (es) | Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos | |
| HRP20210038T1 (hr) | Pirolopirimidini za uporabu u infekciji virusom gripe | |
| HRP20180444T1 (hr) | 9-aminometil-supstituirani tetraciklinski spojevi | |
| AR112264A1 (es) | Derivados de oxoftalazina y oxocinolina como antagonistas de los receptores s1p, composición farmacéutica que los comprende y su uso para el tratamiento de enfermedades fibróticas, autoinmunes y proliferativas | |
| AR080878A1 (es) | Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos. | |
| PH12016502228A1 (en) | Pyrazolopyridines and pyrazolopyrimidines | |
| PE20220253A1 (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| AR079486A1 (es) | Compuestos heterociclicos nitrogenados de oxima, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades proliferativas. | |
| AR091194A1 (es) | TIAZOLES SUSTITUIDOS POR CARBOXAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg | |
| JP2016530338A5 (hr) | ||
| AR081369A1 (es) | Compuestos de 2-5-6-7-tetrahidro-(1,4) oxazepin-3-ilamina o 2,3,6,7-tetrahidro-(1,4) oxazepin-5-ilamina, sus procesos de obtencion y composiciones farmaceuticas que los contienen | |
| RU2016146365A (ru) | Новые дигидрохинолизиноны для лечения и профилактики заражения вирусом гепатита b | |
| AR099367A1 (es) | Inhibidores de la tirosina quinasa de bruton | |
| PE20161443A1 (es) | Compuestos | |
| AR092876A1 (es) | Inhibidores no nucleosidos de la transcriptasa inversa | |
| JP2017511357A5 (hr) | ||
| CR20190261A (es) | Inhibidores de la tirosina quinasa de bruton | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 |